Genocea gains on 12-month HSV data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $3.77 (95%) to $7.74 on Thursday after reporting 12-month data from a Phase II trial

Read the full 205 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE